| pubmed-article:19843887 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0278791 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C1327944 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19843887 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:19843887 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19843887 | pubmed:dateCreated | 2010-1-22 | lld:pubmed |
| pubmed-article:19843887 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:abstractText | Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients. Thirty-one patients received either 375 mg/m(2) (n = 3) or 500 mg/m(2) (n = 28) of lumiliximab in combination with FCR for 6 cycles. The toxicity profile was similar to that previously reported for FCR in treatment of relapsed CLL. The overall response rate was 65%, with 52% of patients achieving a complete response (CR), which compares favorably with the CR rate previously reported for the FCR regimen alone in relapsed CLL. The estimated median progression-free survival for all responders was 28.7 months. The addition of lumiliximab to FCR therapy is feasible, achieves a high CR rate, and does not appear to enhance toxicity in previously treated patients with CLL. A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL. This trial was registered at clinicaltrials.gov as NCT00103558. | lld:pubmed |
| pubmed-article:19843887 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19843887 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19843887 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19843887 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19843887 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:KippsThomas... | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:ByrdJohn CJC | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:FlinnIan WIW | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:O'BrienSusanS | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:HarrisSarahS | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:LeighBryanB | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:TangriShabnam... | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:WierdaWilliam... | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:LinThomas STS | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:HughesSteveS | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:MolinaArturoA | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:HeeremaNylaN | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:WoodworthJame... | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:WynneDeeD | lld:pubmed |
| pubmed-article:19843887 | pubmed:author | pubmed-author:CastroJanuaro... | lld:pubmed |
| pubmed-article:19843887 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19843887 | pubmed:day | 21 | lld:pubmed |
| pubmed-article:19843887 | pubmed:volume | 115 | lld:pubmed |
| pubmed-article:19843887 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19843887 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19843887 | pubmed:pagination | 489-95 | lld:pubmed |
| pubmed-article:19843887 | pubmed:dateRevised | 2011-7-20 | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:meshHeading | pubmed-meshheading:19843887... | lld:pubmed |
| pubmed-article:19843887 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19843887 | pubmed:articleTitle | Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. | lld:pubmed |
| pubmed-article:19843887 | pubmed:affiliation | The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. john.byrd@osumc.edu | lld:pubmed |
| pubmed-article:19843887 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19843887 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19843887 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:19843887 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| pubmed-article:19843887 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19843887 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19843887 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19843887 | lld:pubmed |
